Stock listing
NASDAQ:ACXP Acurx Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of Acurx Pharmaceuticals, Inc.
Follow Acurx Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ACXP
$1.04 USD +0.04 (+4.0%)
Close on Nov 20, 2026
- Day range
- $1.02 – $1.12 USDNov 20, 2026
- Volume
- 154,309 sharesNov 20, 2026
- Market cap
- $6.30M USDAt the close on Nov 20, 2026 · price × 6.06M shares outstanding
- 52-week range
- $0.90 – $7.54 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $118,900 USDMedian day 82,532 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ACXP · Home | $1.04 USD | +0.04 (+4.0%) | 154,309 | $1.11 | $1.12 | $1.02 | $1.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ACXP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.04 | +0.04 | +4.0% | $1.11 | $1.12 | $1.02 | 154,309 | |
| $1.00 | +0.01 | +1.0% | $1.03 | $1.03 | $0.96 | 78,489 | |
| $0.99 | +0.055 | +5.9% | $1.00 | $1.03 | $0.954 | 232,223 | |
| $0.935 | -0.025 | -2.6% | $1.00 | $1.04 | $0.90 | 116,912 | |
| $0.96 | -0.025 | -2.5% | $1.04 | $1.04 | $0.92 | 223,447 | |
| $0.985 | -0.045 | -4.4% | $1.05 | $1.06 | $0.98 | 159,022 | |
| $1.03 | -0.01 | -1.0% | $1.05 | $1.08 | $1.03 | 98,551 | |
| $1.04 | -0.02 | -1.9% | $1.06 | $1.09 | $1.02 | 66,352 | |
| $1.06 | 0.00 | 0.0% | $1.06 | $1.123 | $1.06 | 118,739 | |
| $1.06 | +0.114 | +12.1% | $1.01 | $1.08 | $1.01 | 122,243 | |
| $0.946 | -0.084 | -8.2% | $1.11 | $1.11 | $0.946 | 188,458 | |
| $1.03 | +0.01 | +1.0% | $1.07 | $1.076 | $1.016 | 168,302 | |
| $1.02 | -0.05 | -4.7% | $1.07 | $1.111 | $1.01 | 206,417 | |
| $1.07 | +0.03 | +2.9% | $1.08 | $1.12 | $1.045 | 143,678 | |
| $1.04 | -0.03 | -2.8% | $1.09 | $1.103 | $1.035 | 63,193 | |
| $1.07 | 0.00 | 0.0% | $1.06 | $1.11 | $1.06 | 64,574 | |
| $1.07 | +0.01 | +0.9% | $1.08 | $1.08 | $1.05 | 61,179 | |
| $1.06 | -0.025 | -2.3% | $1.08 | $1.096 | $1.05 | 58,323 | |
| $1.085 | -0.05 | -4.4% | $1.12 | $1.135 | $1.081 | 64,135 | |
| $1.135 | -0.005 | -0.4% | $1.135 | $1.14 | $1.12 | 22,151 | |
| $1.14 | -0.01 | -0.9% | $1.16 | $1.185 | $1.14 | 26,544 | |
| $1.15 | +0.01 | +0.9% | $1.18 | $1.18 | $1.13 | 20,961 | |
| $1.14 | 0.00 | 0.0% | $1.16 | $1.18 | $1.115 | 68,303 | |
| $1.14 | +0.04 | +3.6% | $1.14 | $1.146 | $1.10 | 51,098 | |
| $1.10 | -0.07 | -6.0% | $1.18 | $1.19 | $1.069 | 164,832 | |
| $1.17 | +0.02 | +1.7% | $1.20 | $1.219 | $1.15 | 101,503 | |
| $1.15 | -0.05 | -4.2% | $1.20 | $1.22 | $1.15 | 87,573 | |
| $1.20 | -0.08 | -6.3% | $1.29 | $1.29 | $1.20 | 99,674 | |
| $1.28 | +0.01 | +0.8% | $1.28 | $1.30 | $1.25 | 80,819 | |
| $1.27 | +0.02 | +1.6% | $1.24 | $1.28 | $1.24 | 41,145 | |
| $1.25 | -0.05 | -3.8% | $1.281 | $1.281 | $1.24 | 74,937 | |
| $1.30 | -0.01 | -0.8% | $1.32 | $1.33 | $1.28 | 78,042 | |
| $1.31 | 0.00 | 0.0% | $1.30 | $1.33 | $1.28 | 42,200 | |
| $1.31 | +0.04 | +3.1% | $1.25 | $1.36 | $1.25 | 110,872 | |
| $1.27 | +0.01 | +0.8% | $1.28 | $1.28 | $1.245 | 82,492 | |
| $1.26 | 0.00 | 0.0% | $1.27 | $1.295 | $1.25 | 64,944 | |
| $1.26 | -0.045 | -3.4% | $1.32 | $1.32 | $1.23 | 130,517 | |
| $1.305 | -0.035 | -2.6% | $1.38 | $1.38 | $1.27 | 162,116 | |
| $1.34 | -0.02 | -1.5% | $1.36 | $1.36 | $1.33 | 52,785 | |
| $1.36 | 0.00 | 0.0% | $1.38 | $1.38 | $1.35 | 134,020 | |
| $1.36 | -0.01 | -0.7% | $1.39 | $1.39 | $1.345 | 48,071 | |
| $1.37 | +0.01 | +0.7% | $1.36 | $1.385 | $1.35 | 58,697 | |
| $1.36 | +0.03 | +2.3% | $1.34 | $1.391 | $1.305 | 156,188 | |
| $1.33 | -0.06 | -4.3% | $1.39 | $1.41 | $1.31 | 280,635 | |
| $1.39 | 0.00 | 0.0% | $1.36 | $1.419 | $1.36 | 57,399 | |
| $1.39 | +0.01 | +0.7% | $1.386 | $1.41 | $1.38 | 70,433 | |
| $1.38 | +0.025 | +1.8% | $1.37 | $1.39 | $1.36 | 61,268 | |
| $1.355 | -0.035 | -2.5% | $1.39 | $1.40 | $1.35 | 82,106 | |
| $1.39 | -0.01 | -0.7% | $1.40 | $1.42 | $1.38 | 84,352 | |
| $1.40 | 0.00 | 0.0% | $1.41 | $1.41 | $1.38 | 64,705 | |
| $1.40 | -0.01 | -0.7% | $1.41 | $1.425 | $1.38 | 58,784 | |
| $1.41 | -0.02 | -1.4% | $1.413 | $1.43 | $1.41 | 32,569 | |
| $1.43 | +0.01 | +0.7% | $1.41 | $1.46 | $1.41 | 88,565 | |
| $1.42 | +0.02 | +1.4% | $1.40 | $1.42 | $1.39 | 47,678 | |
| $1.40 | -0.03 | -2.1% | $1.42 | $1.42 | $1.39 | 51,590 | |
| $1.43 | +0.03 | +2.1% | $1.41 | $1.44 | $1.40 | 82,532 | |
| $1.40 | -0.05 | -3.4% | $1.43 | $1.43 | $1.38 | 109,675 | |
| $1.45 | +0.01 | +0.7% | $1.44 | $1.45 | $1.40 | 111,676 | |
| $1.44 | -0.02 | -1.4% | $1.47 | $1.47 | $1.42 | 69,740 | |
| $1.46 | +0.03 | +2.1% | $1.43 | $1.479 | $1.42 | 86,862 | |
| $1.43 | +0.02 | +1.4% | $1.42 | $1.46 | $1.39 | 146,082 | |
| $1.41 | +0.01 | +0.7% | $1.41 | $1.445 | $1.40 | 87,729 | |
| $1.40 | -0.07 | -4.8% | $1.47 | $1.49 | $1.395 | 132,653 | |
| $1.47 | +0.02 | +1.4% | $1.45 | $1.53 | $1.45 | 84,594 | |
| $1.45 | +0.01 | +0.7% | $1.41 | $1.46 | $1.39 | 132,202 |
Splits
1 split · NASDAQ:ACXP · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:ACXP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update
Latest earnings call · Nov 12, 2026
Acurx Pharmaceuticals (NASDAQ:ACXP) Q3 2026 Earnings Call
Replay and transcript
Latest news
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2026 results and provides business update
Nov 12, 2026
Closed $0.985 (-4.4%) on Nov 12, 2026
Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
Oct 26, 2026
Closed $1.09 (-4.4%) on Oct 26, 2026
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
Oct 21, 2026
Closed $1.15 (+0.9%) on Oct 21, 2026
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
Oct 5, 2026
Closed $1.31 (+3.1%) on Oct 5, 2026
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
Sep 29, 2026
Closed $1.31 (-2.6%) on Sep 29, 2026
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures
Sep 14, 2026
Closed $1.39 (-0.7%) on Sep 14, 2026
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
Aug 17, 2026
Closed $1.65 (+18.3%) on Aug 17, 2026
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
Aug 14, 2026
Closed $1.40 (-5.7%) on Aug 14, 2026
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
Aug 12, 2026
Closed $1.54 (+4.8%) on Aug 12, 2026
Acurx Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 124 in all · newest Nov 12, 2026 · oldest 2021
- Calls
- 19 calls with a replay · 19 with a transcript · latest Nov 12, 2026
- Decks
- 16 decks · latest Oct 20, 2025
Where Acurx Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ACXP · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ACXP | BOATS | United States | USD |
| gettex:3ZO0 | gettex | Germany | EUR |
| LS Exchange:A41DXH | LS Exchange | Germany | EUR |
| Frankfurt:3ZO0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A41DXH | Lang & Schwarz | Germany | EUR |
| Munich:3ZO0 | Munich | Germany | EUR |
Valuation
Price/book 0.9× against a median of 1.3×: 4th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$3.35M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.31
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Acurx Pharmaceuticals, Inc. · NASDAQ:ACXP | US$6.30M | −US$3.35M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| Aligos Therapeutics, Inc. · NASDAQ:ALGS | US$6.64M | −US$12.55M | n/a | −2.1× | n/a | 0.6× | n/a | 1.1× | 1.63 |
| ZEO ScientifiX Inc. · OTC:ZEOX | US$6.51M | US$5.27M | n/a | 1.0× | n/a | n/a | −106.2% | n/a | 0.54 |
| FibroBiologics, Inc. · NASDAQ:FBLG | US$6.34M | US$5.17M | n/a | n/a | n/a | 3.5× | n/a | 0.0× | 0.34 |
| GT Biopharma, Inc. · NASDAQ:GTBP | US$6.33M | −US$3.60M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | 1.57 |
| Kyntra Bio, Inc. · NASDAQ:KYNB | US$6.32M | −US$33.97M | n/a | −6.4× | n/a | n/a | −326.0% | n/a | 1.58 |
| TrivarX Limited · ASX:TRI | US$6.11M | US$4.58M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | n/a |
| Enveric Biosciences, Inc. · NASDAQ:ENVB | US$6.04M | US$429,455 | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 0.76 |
| Medicofarma Biotech Spolka Akcyjna · NEWCONNECT:MDB | US$6.03M | US$6.03M | n/a | 314× | n/a | 5.4× | n/a | 0.0× | n/a |
| Addex Therapeutics Ltd · SIX:ADXN | US$5.96M | US$5.13M | n/a | 68.2× | n/a | 2.6× | n/a | 0.0× | n/a |
| Argenica Therapeutics Ltd · ASX:AGN | US$5.95M | US$1.74M | n/a | n/a | n/a | 1.5× | n/a | 0.0× | n/a |
| Median of the others | US$6.21M | US$3.16M | 1.0× | 1.3× | −216.1% | 0.0× | 1.17 |
Forecasts
2 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 17.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.02 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| David P. Luci | President and Chief Executive Officer |
| Robert G. Shawah | Co-Founder & Chief Financial Officer |
| Robert J. DeLuccia | Executive Chairman |
Board
| Director | Role |
|---|---|
| Robert J. DeLuccia | Executive Chairman |
| Carl Sailer | Director |
| David P. Luci | President and Chief Executive Officer |
| Jack H. Dean | Director |
| James Donohue | Director |
| Joseph C. Scodari | Director |
| Thomas Harrison | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q3 2026 Earnings Call | Thu, Nov 12, 2026 · 4:00 PM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q2 2026 Earnings Call | Fri, Aug 14, 2026 · 8:00 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q1 2026 Earnings Call | Tue, May 12, 2026 · 8:00 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q4 2025 Earnings Call | Fri, Mar 13, 2026 · 8:00 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q3 2025 Earnings Call | Wed, Nov 12, 2025 · 8:00 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q2 2025 Earnings Call | Tue, Aug 12, 2025 · 8:00 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q1 2025 Earnings Call | Tue, May 13, 2025 · 8:00 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q4 2024 Earnings Call | Tue, Mar 18, 2025 · 8:00 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q3 2024 Earnings Call | Wed, Nov 13, 2024 · 8:00 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q2 2024 Earnings Call | Fri, Aug 09, 2024 · 8:00 AM ET | Replay |
All 19 calls
| Call | When | Status |
|---|---|---|
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q1 2024 Earnings Call | Wed, May 15, 2024 · 8:00 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q4 2023 Earnings Call | Mon, Mar 18, 2024 · 8:00 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q3 2023 Earnings Call | Tue, Nov 14, 2023 · 8:00 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q2 2023 Earnings Call | Mon, Aug 14, 2023 · 8:00 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q1 2023 Earnings Call | Fri, May 12, 2023 · 8:00 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q2 2022 Earnings Call | Tue, Aug 16, 2022 · 8:30 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q1 2022 Earnings Call | Wed, May 11, 2022 · 8:30 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q4 2022 Earnings Call | Wed, Mar 16, 2022 · 8:00 AM ET | Replay |
| Acurx Pharmaceuticals (NASDAQ:ACXP) Q2 2021 Earnings Call | Tue, Aug 17, 2021 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −4.4% |
| Q2 2026 | Aug 13, 2026 · After close | −5.7% |
| Q1 2026 | May 11, 2026 · After close | −6.0% |
| Q4 2025 | Mar 13, 2026 | −4.0% |
| Q3 2025 | Nov 12, 2025 · Before open | −10.8% |
| Q2 2025 | Aug 11, 2025 · After close | −1.0% |
| Q1 2025 | May 12, 2025 · After close | −3.8% |
| Q4 2024 | Mar 17, 2025 · Before open | +2.6% |
| Q3 2024 | Nov 12, 2024 · After close | −1.6% |
| Q2 2024 | Aug 8, 2024 · After close | −1.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | +7.7% |
| Q4 2023 | Mar 15, 2024 · After close | −4.8% |
| Q3 2023 | Nov 13, 2023 · After close | −2.9% |
| Q2 2023 | Aug 11, 2023 · After close | −8.4% |
| Q1 2023 | May 12, 2023 · Before open | −8.5% |
| Q4 2022 | Mar 15, 2023 · After close | −1.5% |
| Q3 2022 | Nov 10, 2022 · After close | +1.8% |
| Q2 2022 | Aug 12, 2022 · After close | +3.7% |
| Q1 2022 | May 10, 2022 · After close | −4.3% |
| Q4 2021 | Mar 16, 2022 · After close | +1.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| IDWeek 2025 | Conference | 10 slides | Oct 20, 2025 |
| Investor Presentation (September 2025) | Investor deck | 23 slides | September 2025 |
| Technical Presentation (June 2025) | Technical | 10 slides | Jun 5, 2025 |
| Peggy Lillis Foundation Inaugural CDI Scientific Symposium 2024 | Conference | 19 slides | November 2024 |
| 8th International Clostridioides difficile Symposium (ICDS) 2024 | Conference | 15 slides | Sep 17, 2024 |
| Technical Presentation (September 2024) | Technical | 16 slides | September 2024 |
| Anaerobe 2024 | Conference | 19 slides | July 2024 |
| ESCMID 2024, Barcelona | Conference | 13 slides | Apr 20, 2024 |
| IPO Roadshow (April 2024) | IPO roadshow | 23 slides | Apr 2, 2024 |
| IDWeek 2023 | Conference | 10 slides | Oct 12, 2023 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| IDWeek 2023 | Conference | 14 slides | October 2023 |
| World Antimicrobial Resistance Conference 2023 | Conference | 15 slides | Sep 7, 2023 |
| ECCMID 2023 Pipeline Corner | Conference | 11 slides | Apr 15, 2023 |
| ID Week 2022 | Conference | 17 slides | October 2022 |
| IPO Roadshow (June 2021) | IPO roadshow | 22 slides | Jun 11, 2021 |
| IDWeek 2019 | Conference | 13 slides | 2019 |
Financings
| Raise | Date |
|---|---|
| Registered direct offering of shares of common stock (or pre-funded warrants) with concurrent unregistered short-term warrants Closed: US$2.5M raised · US$3.03 a share · Warrants at US$2.78 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Apr 16, 2026 |
| Warrant exercise of existing warrants exercised for shares of common stock Announced: about US$2.67M · US$0.6 a share · Warrants at US$0.425 for 60 months Use of proceeds: Working capital and general corporate purposes | Jun 17, 2025 |
| Equity line of credit Announced: raise Buyers: Lincoln Park Capital (equity line of credit for up to $12 million of additional funding) | May 13, 2025 |
| Registered direct offering of shares of common stock with unregistered short-term warrants Closed: US$1.1M raised · US$0.4 a share · Warrants at US$0.4 for 24 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Mar 10, 2025 |
| Registered direct offering of shares of common stock with unregistered warrants Announced: about US$2.5M · US$1.015 a share · Warrants at US$0.9 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Jan 6, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$6.00 a share on Jun 24, 2021.
- Price
- US$6.00 a share
- Shares offered
- 2,500,000 shares of common stock
- Offering size
- US$15 million
- Underwriters' option
- Up to 375,000 more shares
- Listing
- ACXP on the Nasdaq Capital Market
- Underwriters
- Alexander Capital, L.P., Network 1 Financial Securities, Inc. · In the order on the cover
- Shares delivered
- On or about Jun 29, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 5, 2021 |
| Filed publicly | May 27, 2021 |
| Amended once | Jun 11, 2021 |
| Shares registered with an exchange | Jun 23, 2021 |
| Declared effective by the SEC | Jun 24, 2021 |
| Final prospectus, with the price | Jun 28, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 28, 2021 |
| EFFECT · Notice that a registration is effective | Jun 24, 2021 |
| CERT · Exchange's certificate of listing | Jun 24, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 23, 2021 |
| CORRESP · Letter to the SEC | Jun 22, 2021 |
| CORRESP · Letter to the SEC | Jun 22, 2021 |
| FWP · Free writing prospectus | Jun 11, 2021 |
| S-1/A · Registration statement, amended | Jun 11, 2021 |
| S-1 · Registration statement | May 27, 2021 |
| CORRESP · Letter to the SEC | May 26, 2021 |
All 15 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | May 21, 2021 |
| DRSLTR · Letter to the SEC with a draft | May 10, 2021 |
| DRS/A · Draft registration statement, amended | May 10, 2021 |
| UPLOAD · Letter from the SEC | Apr 30, 2021 |
| DRS · Draft registration statement | Apr 5, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 28, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 1.83M | 5.40M | 6.04M | 4.75M | 2.03M | 2.20M | 3.51M |
| Selling, general and administrative | 6.26B | 8.70M | 8.53M | 7.34M | 208.3K | 2.40M | 2.42M |
| Operating income | -8.09M | -14.1M | -14.6M | -12.1M | -12.9M | -4.60M | -5.93M |
| Depreciation and amortization | 14.1M | 14.6M | 12.1M | 66.5K | 4.60M | 5.93M | |
| EBITDA | 0 | 232 | 224 | -12.8M | 0 | 0 | |
| Interest expense | 1.22K | 66.5K | 0 | 0 | |||
| Income before tax | -7.97M | -14.1M | -14.6M | -12.1M | -12.7M | -4.60M | -5.93M |
| Income tax | -14.1B | -14.6K | 0 | -66.5K | 0 | -5.93K | |
| Net income | -7.97M | -14.1M | -14.6M | -12.1M | -12.7M | -4.60M | -5.93M |
| Earnings per share, basic | -5.32 | -17.45 | -1.15 | -1.12 | -1.49 | -0.74 | -12.43 |
| Earnings per share, diluted | -5.32 | -17.45 | -1.15 | -1.12 | -1.49 | -0.74 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.56M | 3.71M | 7.47M | 9.11M | 13.0M | 3.18M | 2.48M |
| Receivables | 48.4K | 51.1K | 129.2K | ||||
| Current assets | 7.69M | 3.86M | 7.71M | 9.38M | 13.3M | 3.22M | 2.53M |
| Total assets | 7.69M | 3.86M | 7.71M | 9.38M | 13.3M | 3.22M | 2.53M |
| Accounts payable | 3.81K | 29.5K | 63.4K | 2.30K | |||
| Current liabilities | 2.42M | 3.24M | 3.04M | 2.06M | 843.9K | 472.6K | 1.71M |
| Long-term debt | 49.9K | ||||||
| Total debt | 66.5K | ||||||
| Total liabilities | 2.42M | 3.24M | 3.04M | 2.06M | 843.9K | 522.4K | 1.71M |
| Shareholders' equity | 5.27M | 615.1K | 4.67M | 7.32M | 12.4M | 2.70M | 819.9K |
| Shares outstanding | 2.35M | 851.5K | 14.5M | 11.6M | 10.2M | 11.6M | 477.1K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -6.79M | -10.4M | -9.80M | -7.54M | -5.01M | -3.35M | -3.99M |
| Capital spending | 0 | 0 | -5 | 0 | -3 | 0 | 0 |
| Free cash flow | -6.79M | -10.4M | -9.80M | -7.54M | -5.01M | -3.35M | -3.99M |
| Cash from financing | 10.6M | 6.62M | 8.16M | 3.70M | 14.8M | 4.04M | 4.46M |
| Share buybacks | -1.04K | 0 | |||||
| Change in cash | 3.85M | -3.77M | -1.64M | -3.85M | 9.78M | 692.1K | 470.2K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| 8-K · Current report | Nov 13, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2026 | Current report | SEC |
| 8-K · Current report | Oct 16, 2026 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Sep 18, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Sep 17, 2026 | Offer document | SEC |
| S-1 · Registration statement | Sep 8, 2026 | Offer document | SEC |
| ARS · Annual report to shareholders | Sep 1, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Sep 1, 2026 | Meeting notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| DEF 14A · Proxy statement | Sep 1, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 424B3 · Prospectus | May 12, 2026 | Offer document | SEC |
| 424B3 · Prospectus | May 12, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 12, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | May 12, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| CORRESP · Letter to the SEC | May 7, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 7, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 7, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 7, 2026 | Other filings | SEC |
| S-1 · Registration statement | May 4, 2026 | Offer document | SEC |
| S-1 · Registration statement | May 4, 2026 | Offer document | SEC |
| D | Apr 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 16, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Apr 16, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 9, 2026 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Feb 12, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Feb 11, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 9, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 9, 2026 | Other filings | SEC |
| S-1 · Registration statement | Feb 2, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 7, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 2, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | Dec 30, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 424B3 · Prospectus | Nov 10, 2025 | Offer document | SEC |
| S-1 · Registration statement | Oct 20, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 22, 2025 | Current report | SEC |
| 8-K · Current report | Sep 19, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 11, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Aug 5, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Aug 5, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jul 31, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Jul 25, 2025 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Jul 24, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 21, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 21, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 17, 2025 | Meeting outcome | SEC |
| S-1 · Registration statement | Jul 14, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jul 14, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jul 9, 2025 | Offer document | SEC |
| D | Jun 27, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 20, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | May 30, 2025 | Other filings | SEC |
| 424B3 · Prospectus | May 29, 2025 | Offer document | SEC |
| ARS · Annual report to shareholders | May 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 29, 2025 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | May 27, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 27, 2025 | Other filings | SEC |
| S-1 · Registration statement | May 21, 2025 | Offer document | SEC |
| D | May 20, 2025 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | May 19, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Apr 15, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 10, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 10, 2025 | Other filings | SEC |
| S-1 · Registration statement | Apr 4, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 28, 2025 | Current report | SEC |
| D | Mar 20, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 20, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 18, 2025 | Results | SEC |
| S-8 · Registration statement for employee plans | Mar 17, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 17, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 17, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Mar 10, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 26, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Feb 7, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Feb 4, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 4, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jan 31, 2025 | Offer document | SEC |
| D | Jan 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 8, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Jan 7, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 7, 2025 | Material contract | SEC |
| 424B3 · Prospectus | Jan 6, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2024 | Meeting outcome | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| RW · Request to withdraw a registration | Apr 17, 2024 | Other filings | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2024 | Insider trade | SEC |
| FWP · Free writing prospectus | Apr 2, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Mar 29, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 18, 2024 | Results | SEC |
| S-1 · Registration statement | Mar 18, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 15, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 15, 2024 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 15, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Nov 15, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2023 | Current report | SEC |
| 8-K · Current report | Oct 2, 2023 | Current report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 424B3 · Prospectus | Jul 13, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 11, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 6, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 5, 2023 | Other filings | SEC |
| S-1 · Registration statement | Jun 29, 2023 | Offer document | SEC |
| 8-K · Current report | Jun 20, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 424B3 · Prospectus | May 18, 2023 | Offer document | SEC |
| 424B5 · Prospectus | May 17, 2023 | Offer document | SEC |
| 8-K · Current report | May 17, 2023 | Material contract | SEC |
| 10-Q · Quarterly report | May 12, 2023 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 27, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2023 | Meeting notice | SEC |
| 8-K · Current report | Mar 16, 2023 | Results | SEC |
| S-8 · Registration statement for employee plans | Mar 15, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 15, 2023 | Annual report | SEC |
| 4 · Change in ownership | Feb 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2023 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Nov 14, 2022 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2022 | Quarterly report | SEC |
| 424B3 · Prospectus | Sep 23, 2022 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 23, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 20, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 19, 2022 | Other filings | SEC |
| S-1 · Registration statement | Sep 14, 2022 | Offer document | SEC |
| 8-K · Current report | Aug 15, 2022 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2022 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 29, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2022 | Insider trade | SEC |
| 424B5 · Prospectus | Jul 25, 2022 | Offer document | SEC |
| 8-K · Current report | Jul 25, 2022 | Results | SEC |
| EFFECT · Notice that a registration is effective | Jul 12, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 7, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 7, 2022 | Other filings | SEC |
| S-3 · Registration statement | Jul 1, 2022 | Offer document | SEC |
| 8-K · Current report | Jun 7, 2022 | Meeting outcome | SEC |
| 8-K · Current report | May 11, 2022 | Results | SEC |
| 10-Q · Quarterly report | May 10, 2022 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2022 | Meeting notice | SEC |
| 8-K · Current report | Mar 17, 2022 | Results | SEC |
| S-8 · Registration statement for employee plans | Mar 16, 2022 | Offer document | SEC |
| 10-K · Annual report | Mar 16, 2022 | Annual report | SEC |
This page holds 200 of 248 filings. Open Filings
Cap table
Built by 6ix from Acurx Pharmaceuticals, Inc.’s releases · as of Nov 12, 2026
- Common shares
- 6,058,135
- Fully diluted
- 6,058,135
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 6,058,135 | Nov 12, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$2.78 · expire about Apr 2028 |
| Warrants · US$0.40 · expire about Mar 2027 |
Share count over time
| Count | Shares |
|---|---|
| Nov 12, 2026 | 6,058,135 |
| Sep 30, 2026 | 5,879,237 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Thomas Harrison Other companies: Agenus Inc. (Director · Since at least Aug 7, 2024); Advanced Flower Capital Inc. (Director · Since at least Mar 18, 2021); Zynerba Pharmaceuticals Inc (Director · Aug 4, 2015 – Jun 6, 2018 · Past); Fifth Street Asset Management Inc (Director · Oct 29, 2014 – Dec 8, 2017 · Past); PLx Pharma Inc (Director · Mar 12, 2014 – Jan 17, 2017 · Past); rVue Holdings Inc (Director · Sep 19, 2013 – Dec 3, 2013 · Past); Epocrates Inc (Director · Feb 1, 2011 – Mar 12, 2013 · Past); Omnicom Group Inc. (Chrmn/CEO Divers. Agency Serv. · May 4, 2006 – Mar 31, 2010 · Past); Morgans Hotel Group Company (Director · Feb 13, 2006 – May 17, 2012 · Past) | Director · Since at least Jun 24, 2021 |
| David P. Luci Other companies: Enveric Biosciences, Inc. (Director · Feb 8, 2018 – Aug 20, 2018 · Past); PLx Pharma Inc (Director · Mar 12, 2014 – Jan 17, 2017 · Past); Abeona Therapeutics Inc. (Director · Jan 4, 2007 – Nov 2, 2009 · Past); Bioenvision Inc (EVP & General Counsel · Feb 28, 2006 – Jul 10, 2007 · Past) | President and CEO, Director · Since at least Jun 24, 2021 |
| Jack H Dean Other companies: PLx Pharma Inc (Director · Mar 12, 2014 – Jan 17, 2017 · Past) | Director · Since at least Jun 24, 2021 |
| Joseph C. Scodari Other companies: OptiNose (Director · Jun 6, 2019 – Jun 8, 2022 · Past) | Director · Since at least Jun 24, 2021 |
| Carl Sailer | Director · Since at least Jun 24, 2021 |
| Jack H. Dean | Director · Since at least Nov 4, 2026 |
| James Donohue | Director · Since at least Jun 24, 2021 |
| Robert G. Shawah | Chief Financial Officer · Since at least Feb 23, 2024 |
| Robert J. DeLuccia | Executive Chairman · Since at least Jul 27, 2022 |
Log in to ask 6ix AI your own questions about Acurx Pharmaceuticals, Inc.